胰腺癌、影像组学与人工智能
综述胰腺导管腺癌(PDAC)影像组学与人工智能研究进展:基于增强CT的定量影像特征、影像组学标签和深度学习模型可能作为预后与预测生物标志物,用于判断肿瘤侵袭性、治疗反应和患者预后,但指标不稳定且缺乏外部验证,尚不具备临床落地条件。
要点
- PDAC诊断时按增强CT分为可切除、交界可切除、不可切除和转移四类,结构化放射学模板有用但有限。
- 影像组学与动态影像特征可提供临床结局信息,并构建基于影像组学标签或影像表型的临床模型。
- 定量影像用于PDAC临床实践尚不成熟,主要障碍是指标不稳定和缺乏外部验证。
核心结论
- 定量影像特征可能作为预后和预测生物标志物用于临床决策,助力晚期PDAC的个体化管理。
- 深度学习与卷积神经网络可帮助定义与PDAC生物学行为和侵袭性相关的特征,从而基于这些特征预测结局。
- 利用此类综合集成影像组学模型,预测肿瘤表型、治疗反应和患者预后可能是可行的。
- 尽管结果令人期待,定量影像尚未准备好在PDAC中进入临床实施。
研究设计与样本
- 综述类文章,检索范围与纳入文献数量原文未报告。
- 讨论对象为胰腺导管腺癌(PDAC)患者,诊断时依据增强CT分为可切除、交界可切除、不可切除和转移性疾病四类。
- 涉及影像组学、动态影像特征、深度学习与卷积神经网络等定量影像分析方法。
诊断标准与关键数值
- PDAC诊断时基于增强CT分为可切除、交界可切除、不可切除和转移性疾病四类。
- 结构化放射学模板用于PDAC初始分级和分期,但存在局限。
- 需要明确肿瘤侵袭性和显微镜下疾病分期,以确保合适的治疗分配。
临床应用与阅片要点
- 结构化放射学模板可用于PDAC初始分级和分期,但原文指出其有用而有限。
- 影像组学特征和影像表型可能用于构建临床模型,作为预后和预测生物标志物辅助临床决策。
- 深度学习与卷积神经网络可帮助定义与PDAC生物学和侵袭性相关的特征。
- 定量影像尚未准备好在PDAC中临床实施,主要限制为指标不稳定和缺乏外部验证。
局限性
- 定量影像尚未准备好在PDAC中进入临床实施。
- 局限性包括指标不稳定和缺乏外部验证。
- 需要大型且标注规范的数据集(含人口学、血液标志物、基因组学等相关语义特征)、图像 harmonisation、稳健的影像组学分析、以有临床意义的任务为输出、与金标准(如TNM或治疗前分类)比较以及完全独立的验证队列,才能开发可信的影像组学与人工智能方案。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Patients with pancreatic ductal adenocarcinoma (PDAC) are generally classified into four categories based on contrast-enhanced CT at diagnosis: resectable, borderline resectable, unresectable, and metastatic disease. In the initial grading and staging of PDAC, structured radiological templates are useful but limited, as there is a need to define the aggressiveness and microscopic disease stage of these tumours to ensure adequate treatment allocation. Quantitative imaging analysis allows radiomics and dynamic imaging features to provide information of clinical outcomes, and to construct clinical models based on radiomics signatures or imaging phenotypes. These quantitative features may be used as prognostic and predictive biomarkers in clinical decision-making, enabling personalised management of advanced PDAC. Deep learning and convolutional neural networks also provide high level bioinformatics tools that can help define features associated with a given aspect of PDAC biology and aggressiveness, paving the way to define outcomes based on these features. Thus, the prediction of tumour phenotype, treatment response and patient prognosis may be feasible by using such comprehensive and integrated radiomics models. Despite these promising results, quantitative imaging is not ready for clinical implementation in PDAC. Limitations include the instability of metrics and lack of external validation. Large properly annotated datasets, including relevant semantic features (demographics, blood markers, genomics), image harmonisation, robust radiomics analysis, clinically significant tasks as outputs, comparisons with gold-standards (such as TNM or pretreatment classifications) and fully independent validation cohorts, will be required for the development of trustworthy radiomics and artificial intelligence solutions to predict PDAC aggressiveness in a clinical setting.
引用
- Marti-Bonmati, Cerdá-Alberich, Pérez-Girbés, et al. Pancreatic cancer, radiomics and artificial intelligence. Br J Radiol. 2022. PMID: 35687700. doi:10.1259/bjr.20220072
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。